ArticleFrontiers in medicine2026
Mast cell burden and immunophenotype of Chinese patients with cutaneous mastocytosis: a 10-year study with focus on the easily neglected pathogenic features.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous mastocytosis (CM) is a heterogeneous disease. Challenges remain in the detailed pathological features and pathogenic factors and their potential correlation in Chinese patients. Objective: This study aimed to characterize the pathological features and immunophenotypes of different CM subtypes in a real-world cohort and to explore the potential correlations between mast cell-related pathogenic features and clinical phenotypes. Methods: A cohort of 88 patients diagnosed with CM by histopathological examination in the Department of Dermatology between 2015 and 2024 was established. Immunohistochemical and clinicopathological analyses were performed. Results: Mast cell burden is associated with CM subtype, with the lowest burden being in telangiectasia macularis eruptive perstans (TMEP), followed by urticaria pigmentosa (UP) and diffuse CM/mastocytoma. High mast cell burden may also be associated with specific clinical morphology (e.g., elevated lesions) and an earlier age of onset. Different clinical subtypes exhibit distinct immunophenotypes. The expression of CD2, CD25, and CD30 may correlate with specific subtypes with high mast cell burden and provide potential value for CM diagnosis and subtyping. TMEP showed pathological differences from other subtypes, particularly in mast cell burden and immunophenotype. Conclusion: Different CM subtypes display distinct mast cell burdens and immunophenotypes, suggesting potential diagnostic value. The diverse clinical phenotypes may be associated with different mast cell burdens. TMEP may represent a unique and rare morphological variant of UP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.